Today Alliqua Biomedical Inc (NASDAQ:ALQA) Reported Decrease in Shorted Shares

June 17, 2018 - By Michael Collier

Alliqua BioMedical, Inc. (NASDAQ:ALQA) Logo

The stock of Alliqua Biomedical Inc (NASDAQ:ALQA) registered a decrease of 20.72% in short interest. ALQA’s total short interest was 125,500 shares in June as published by FINRA. Its down 20.72% from 158,300 shares, reported previously. With 19,600 shares average volume, it will take short sellers 6 days to cover their ALQA’s short positions. The short interest to Alliqua Biomedical Inc’s float is 3.83%.

The stock decreased 0.99% or $0.02 during the last trading session, reaching $2.01. About 6,598 shares traded. Alliqua BioMedical, Inc. (NASDAQ:ALQA) has declined 46.35% since June 17, 2017 and is downtrending. It has underperformed by 58.92% the S&P500.

Alliqua BioMedical, Inc., a regenerative technologies company, commercializes regenerative medical products that assist the body in the repair or replacement of soft tissue. The company has market cap of $10.06 million. It markets MIST Ultrasound Healing Therapy, a painless, noncontact, low-frequency ultrasound to promote healing; Biovance Amniotic Membrane Allograft and Interfyl Human Connective Tissue Matrix that are human biologic regenerative technologies; and TheraBond 3D Antimicrobial Barrier Systems that promotes an optimal wound healing by creating an antimicrobial barrier that helps protect against infection. It currently has negative earnings. The firm also provides contract manufacturing services, including the development, manufacture, and market of high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics.

Another recent and important Alliqua BioMedical, Inc. (NASDAQ:ALQA) news was published by Nasdaq.com which published an article titled: “Investor Expectations to Drive Momentum within Gorman-Rupp, Mistras Group, Inovalon, Johnson Controls …” on June 11, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: